<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513119</url>
  </required_header>
  <id_info>
    <org_study_id>cstc2019jscx-msxmX0230</org_study_id>
    <nct_id>NCT04513119</nct_id>
  </id_info>
  <brief_title>The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis.</brief_title>
  <official_title>The Short-term Efficacy of Novel No-touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma With Cirrhosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the short-term efficacy of novel no-touch combined directional perfusion&#xD;
      radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver cancer is the fourth leading cause of cancer-related deaths globally. Hepatocellular&#xD;
      carcinoma (HCC) accounts for 70% to 85% of primary HCC and is the leading cause of death in&#xD;
      patients with cirrhosis. We developed a novel no-touch combined directional perfusion&#xD;
      radiofrequency ablation system.By inserting two or more electrodes around the tumor and&#xD;
      activating them simultaneously.The hypertonic saline solution can be directed into the focal&#xD;
      tissue from a lateral pore through a tube within the electrode to provide more uniform and&#xD;
      thorough necrosis.The maximum ablation volume was increased while the loss of normal tissue&#xD;
      in the non-injection direction was reduced, thus reducing the incidence of postoperative&#xD;
      complications. Therefore, the purpose of this study was to evaluate the short-term efficacy&#xD;
      of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of&#xD;
      small hepatocellular carcinoma with cirrhosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of local tumor progression (LTP)</measure>
    <time_frame>two-years local tumor progression-free survival</time_frame>
    <description>LTP was defined as the appearance of new tumor foci near 2 cm at the ablative margin after the local eradication of all tumor cells with RFA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor-free survival</measure>
    <time_frame>two-years tumor-free survival</time_frame>
    <description>The tumor did not recur after treatment.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma Stage I</condition>
  <condition>Radiofrequency Ablation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary hepatocellular carcinoma with cirrhosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary hepatocellular carcinoma with a background of cirrhosis&#xD;
&#xD;
          -  Single shot with diameter ≤ 3cm&#xD;
&#xD;
          -  The tumor did not invade portal vein, hepatic vein trunk and secondary branches&#xD;
&#xD;
          -  Child Pugh A/B&#xD;
&#xD;
          -  ICG-R15 ≤ 30%&#xD;
&#xD;
          -  18-70 years old&#xD;
&#xD;
          -  The follow-up time reached 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The follow-up time is less than 2 years&#xD;
&#xD;
          -  multiple lesions or diameter &gt; 3cm&#xD;
&#xD;
          -  Previous history of upper gastrointestinal bleeding or severe hypersplenism&#xD;
&#xD;
          -  Patients with extrahepatic or lymph node metastasis&#xD;
&#xD;
          -  Wish to receive liver transplantation and hepatectomy&#xD;
&#xD;
          -  The lesion is adjacent to the gallbladder, important blood vessels and bile ducts in&#xD;
             the hilum of the liver and important organs around&#xD;
&#xD;
          -  severe bleeding tendency, platelet count &lt; 50 × 10^9/L, or prothrombin time prolonged&#xD;
             &gt; 3s&#xD;
&#xD;
          -  Other anti-tumor therapies were accepted before surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Kuansheng Ma, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Institute of hepatobiliary surgery,Southwest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kai Feng, M.D</last_name>
    <phone>+86-23-13228683383</phone>
    <email>fengkai7688@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of hepatobiliary surgery,Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Institute of hepatobiliary surgery,Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Feng, M.D</last_name>
      <phone>+86-23-13228683383</phone>
      <email>fengkai7688@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Kai Feng, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>fengkai</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

